Avidity Biosciences appoints former Roche SVP Simona Skerjanec as Class II director

Avidity Biosciences, Inc.

Ms. Skerjanec, 59, former Senior Vice President and Global Neuroscience Head at Roche (2015-2023), appointed effective May 14, 2024.
She fills the Class II vacancy resulting from Eric Mosbrooker's resignation in December 2023.
She receives options vesting monthly over three years and cash compensation per the Non-Employee Director Compensation Program.
Board determined she is independent under Nasdaq listing requirements.
No arrangements or transactions requiring disclosure under Item 404(a) of Regulation S-K.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Simona Skerjanec

Director

Avidity Biosciences, Inc.

Effective: 2024-05-14
Filed: May 15, 2024, 7:59 PM ET

appointed Simona Skerjanec, M.Pharm, MBA as a director, effective May 14, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Simona Skerjanec was appointed as Director at Avidity Biosciences, Inc..

Action: appointed
Role: Director

Exact text from the filing

appointed Simona Skerjanec, M.Pharm, MBA as a director, effective May 14, 2024.

View on SEC.gov

Source: SEC EDGAR

accession 0001193125-24-138959

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.